EGFR and non-small cell lung carcinoma: As described for first-second generation EGFR-TKIs and with the same frequency (14%), histologic transformation from NSCLC to SCLC is a known mechanism of resistance to third-generation EGFR-TKIs in second-line osimertinib treatment.